2. |
Sukaina M, Hasan MM, Essar MY. Emergence of Omicron BA.1 and BA.2
variants and concern over vaccine breakthrough infection. Ann Med
Surg (Lond). 2022;79(103941):103941.
doi:10.1016/j.amsu.2022.103941 |
3. |
Zou R, Peng L, Shu D, et al. Antiviral efficacy and safety of
molnupiravir against Omicron variant infection: A randomized controlled
clinical trial. Front Pharmacol. 2022;13:939573.
doi:10.3389/fphar.2022.939573 |
4. |
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir
for oral treatment of Covid-19 in nonhospitalized patients. N Engl
J Med. 2022;386(6):509-520. doi:10.1056/NEJMoa2116044 |
5. |
Siddiqui A, Adnan A, Abbas M, Taseen S, Ochani S, Essar MY. Revival
of the heterologous prime-boost technique in COVID-19: An outlook from
the history of outbreaks. Health Sci Rep. 2022;5(2):e531.
doi:10.1002/hsr2.531 |
6. |
Caraco Y, Crofoot GE, Moncada PA, et al. Phase 2/3 trial of
molnupiravir for treatment of covid-19 in nonhospitalized
adults. NEJM Evid. 2022;1(2).
doi:10.1056/evidoa2100043 |
7. |
Fischer WA 2nd, Eron JJ Jr, Holman W, et al. A phase 2a clinical
trial of molnupiravir in patients with COVID-19 shows accelerated
SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci
Transl Med. 2022;14(628):eabl7430.
doi:10.1126/scitranslmed.abl7430 |
8. |
Khoo SH, Fitzgerald R, Fletcher T, et al. Optimal dose and safety
of molnupiravir in patients with early SARS-CoV-2: a Phase I,
open-label, dose-escalating, randomized controlled study. J
Antimicrob Chemother. 2021;76(12):3286-3295.
doi:10.1093/jac/dkab318 |
9. |
Painter WP, Holman W, Bush JA, et al. Human safety, tolerability,
and pharmacokinetics of molnupiravir, a novel broad-spectrum oral
antiviral agent with activity against SARS-CoV-2. Antimicrob
Agents Chemother. 2021;65(5). doi:10.1128/AAC.02428-20 |
10. |
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that evaluate
healthcare interventions: explanation and elaboration. BMJ.
2009;339(jul21 1):b2700. doi:10.1136/bmj.b2700 |
11. |
Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted
systematic reviews: a new edition of the Cochrane Handbook for
Systematic Reviews of Interventions. Cochrane Database Syst Rev.
2019;10:ED000142. doi:10.1002/14651858.ED000142 |
12. |
RoB 2: A revised Cochrane risk-of-bias tool for randomized trials.
Cochrane.org. Accessed July 6, 2023.
https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials |
13. |
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
doi:10.1136/bmj.327.7414.557 |
14. |
Arribas JR, Bhagani S, Lobo SM, et al. Randomized trial of
molnupiravir or placebo in patients hospitalized with
covid-19. NEJM Evid. 2022;1(2).
doi:10.1056/evidoa2100044 |
15. |
Pitre T, Van Alstine R, Chick G, et al. Antiviral drug treatment
for nonsevere COVID-19: a systematic review and network
meta-analysis. CMAJ. 2022;194(28):E969-E980.
doi:10.1503/cmaj.220471 |
16. |
Lai CC, Wang YH, Chen KH, Chen CH, Wang CY. The clinical efficacy
and safety of anti-viral agents for non-hospitalized patients with
COVID-19: A systematic review and network meta-analysis of randomized
controlled trials. Viruses. 2022;14(8):1706.
doi:10.3390/v14081706 |
17. |
Wen W, Chen C, Tang J, et al. Efficacy and safety of three new
oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for
COVID-19:a meta-analysis. Ann Med. 2022;54(1):516-523.
doi:10.1080/07853890.2022.2034936 |
18. |
Tian L, Pang Z, Li M, et al. Molnupiravir and its antiviral
activity against COVID-19. Front Immunol. 2022;13:855496.
doi:10.3389/fimmu.2022.855496 |
19. |
Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as
monotherapy or in combination with etesevimab on viral load in patients
with mild to moderate COVID-19: A randomized clinical trial: A
randomized clinical trial. JAMA. 2021;325(7):632-644.
doi:10.1001/jama.2021.0202 |
20. |
RECOVERY Collaborative Group, Horby PW, Mafham M, et al.
Casirivimab and imdevimab in patients admitted to hospital with COVID-19
(RECOVERY): a randomised, controlled, open-label, platform
trial. bioRxiv. Published online 2021:2021.06.15.21258542.
doi:10.1101/2021.06.15.21258542 |